Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase
NO_LONGER_AVAILABLE
Status
Conditions
- Acute Lymphoblastic Leukemia
Interventions
- DRUG: suspension of erythrocytes encapsulating L-asparaginase
Sponsor
ERYtech Pharma